It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based serum N-glycan analysis has gained acknowledgment for the diagnosis of breast cancer in recent years. In this study, the possibilities of expanding its application for breast cancer management and surveillance were discovered and evaluated. First, a novel MALDI-TOF platform, IDsys RT, was confirmed to be effective for breast cancer analysis, showing a maximum area under the curve of 0.91. Multiple N-glycan markers were identified and validated using this process, and they were found to be applicable for differentiating recurring breast cancer samples from healthy control or ordinary breast cancer samples. Recurrence samples were especially distinct from non-recurrence samples when N-glycan signatures were sampled in multiple time points and monitored via MALDI-TOF, throughout the therapy. These results suggested the feasibility of MALDI-TOF-based N-glycan analysis for tracking the molecular signatures of breast cancer and predicting recurrence.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Seoul, Republic of Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)
2 R&D Center, NOSQUEST Inc., Seongnam-si, Republic of Korea (GRID:grid.413967.e)
3 Asan Medical Center, University of Ulsan College of Medicine, Department of Laboratory Medicine, Seoul, Republic of Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)
4 Asan Medical Center, Health Screening and Promotion Center, Seoul, Republic of Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)
5 Asan Medical Center, University of Ulsan College of Medicine, Department of Biomedical Sciences, Seoul, Republic of Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)